1075 related articles for article (PubMed ID: 18310189)
1. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.
France EK; Glanz J; Xu S; Hambidge S; Yamasaki K; Black SB; Marcy M; Mullooly JP; Jackson LA; Nordin J; Belongia EA; Hohman K; Chen RT; Davis R;
Pediatrics; 2008 Mar; 121(3):e687-92. PubMed ID: 18310189
[TBL] [Abstract][Full Text] [Related]
2. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations.
Fombonne E; Zakarian R; Bennett A; Meng L; McLean-Heywood D
Pediatrics; 2006 Jul; 118(1):e139-50. PubMed ID: 16818529
[TBL] [Abstract][Full Text] [Related]
3. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of potentially common adverse events associated with the first and second doses of measles-mumps-rubella vaccine.
LeBaron CW; Bi D; Sullivan BJ; Beck C; Gargiullo P
Pediatrics; 2006 Oct; 118(4):1422-30. PubMed ID: 17015532
[TBL] [Abstract][Full Text] [Related]
5. A population-based, multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children.
Glanz J; France E; Xu S; Hayes T; Hambidge S
Pediatrics; 2008 Mar; 121(3):e506-12. PubMed ID: 18310170
[TBL] [Abstract][Full Text] [Related]
6. Thrombocytopenia after immunization of Canadian children, 1992 to 2001.
Jadavji T; Scheifele D; Halperin S;
Pediatr Infect Dis J; 2003 Feb; 22(2):119-22. PubMed ID: 12586974
[TBL] [Abstract][Full Text] [Related]
7. Atopic dermatitis is increased following vaccination for measles, mumps and rubella or measles infection.
Olesen AB; Juul S; Thestrup-Pedersen K
Acta Derm Venereol; 2003; 83(6):445-50. PubMed ID: 14690341
[TBL] [Abstract][Full Text] [Related]
8. [Thrombocytopenic purpura after isolated or combined vaccination against measles, mumps and rubella].
Autret E; Jonville-Béra AP; Galy-Eyraud C; Hessel L
Therapie; 1996; 51(6):677-80. PubMed ID: 9164004
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
[TBL] [Abstract][Full Text] [Related]
10. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age.
Redd SC; King GE; Heath JL; Forghani B; Bellini WJ; Markowitz LE
J Infect Dis; 2004 May; 189 Suppl 1():S116-22. PubMed ID: 15106100
[TBL] [Abstract][Full Text] [Related]
11. Serosurvey of measles, mumps and rubella antibodies in Saudi children.
Al-Mazrou YY; Khalil MK; Tischer A; Al-Jeffri MH; Al-Ghamdi YS; Bakhsh MM; Mishkas AA; Elgizouli SA
Saudi Med J; 2005 Oct; 26(10):1551-4. PubMed ID: 16228054
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
13. Vaccination associated thrombocytopenic purpura in children.
Rajantie J; Zeller B; Treutiger I; Rosthöj S;
Vaccine; 2007 Feb; 25(10):1838-40. PubMed ID: 17126957
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
[TBL] [Abstract][Full Text] [Related]
15. Toward better vaccine safety data and safer vaccination.
Braun MM
Pediatrics; 2008 Mar; 121(3):625-6. PubMed ID: 18310214
[No Abstract] [Full Text] [Related]
16. Vaccines for measles, mumps and rubella in children.
Demicheli V; Rivetti A; Debalini MG; Di Pietrantonj C
Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD004407. PubMed ID: 22336803
[TBL] [Abstract][Full Text] [Related]
17. Lack of association between measles-mumps-rubella vaccination and autism in children: a case-control study.
Mrozek-Budzyn D; Kiełtyka A; Majewska R
Pediatr Infect Dis J; 2010 May; 29(5):397-400. PubMed ID: 19952979
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
[TBL] [Abstract][Full Text] [Related]
19. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
Zignol M; Peracchi M; Tridello G; Pillon M; Fregonese F; D'Elia R; Zanesco L; Cesaro S
Cancer; 2004 Aug; 101(3):635-41. PubMed ID: 15274078
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age.
Yadav S; Thukral R; Chakarvarti A
Indian J Med Res; 2003 Nov; 118():183-6. PubMed ID: 14723482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
